Faron Pharmaceuticals Oy Stock Current Valuation
| FARN Stock | 170.00 2.50 1.49% |
Valuation analysis of Faron Pharmaceuticals helps investors to measure Faron Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Other Non Cash Items is likely to gain to about 1.2 M in 2024, whereas Cash is likely to drop slightly above 5.4 M in 2024. Fundamental drivers impacting Faron Pharmaceuticals' valuation include:
Price Book 156.0929 | Enterprise Value 163.6 M | Enterprise Value Ebitda (3.53) | Price Sales 16.209 |
Overvalued
Today
Please note that Faron Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Faron Pharmaceuticals is based on 3 months time horizon. Increasing Faron Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Faron stock is determined by what a typical buyer is willing to pay for full or partial control of Faron Pharmaceuticals Oy. Since Faron Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Faron Stock. However, Faron Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 170.0 | Real 142.8 | Hype 170.0 |
The intrinsic value of Faron Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Faron Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Faron Pharmaceuticals Oy helps investors to forecast how Faron stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Faron Pharmaceuticals more accurately as focusing exclusively on Faron Pharmaceuticals' fundamentals will not take into account other important factors: Faron Pharmaceuticals Oy Company Current Valuation Analysis
Faron Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Faron Pharmaceuticals Current Valuation | 163.6 M |
Most of Faron Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Faron Pharmaceuticals Oy is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Faron Pharmaceuticals Oy has a Current Valuation of 163.6 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The current valuation for all United Kingdom stocks is notably lower than that of the firm.
Faron Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Faron Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Faron Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Faron Pharmaceuticals by comparing valuation metrics of similar companies.Faron Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Faron Fundamentals
| Return On Equity | -39.61 | ||||
| Return On Asset | -0.7 | ||||
| Current Valuation | 163.6 M | ||||
| Shares Outstanding | 104.62 M | ||||
| Shares Owned By Insiders | 31.81 % | ||||
| Shares Owned By Institutions | 10.35 % | ||||
| Price To Book | 156.09 X | ||||
| Price To Sales | 16.21 X | ||||
| Gross Profit | 803 K | ||||
| EBITDA | (28.37 M) | ||||
| Net Income | (30.94 M) | ||||
| Total Debt | 13.11 M | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (23.81 M) | ||||
| Earnings Per Share | (0.31) X | ||||
| Target Price | 1009.02 | ||||
| Number Of Employees | 34 | ||||
| Beta | 0.33 | ||||
| Market Capitalization | 177.86 M | ||||
| Total Asset | 10.22 M | ||||
| Retained Earnings | (172.21 M) | ||||
| Working Capital | (6.14 M) | ||||
| Net Asset | 10.22 M |
About Faron Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Faron Pharmaceuticals Oy's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Faron Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Faron Pharmaceuticals Oy based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Faron Stock Analysis
When running Faron Pharmaceuticals' price analysis, check to measure Faron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Faron Pharmaceuticals is operating at the current time. Most of Faron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Faron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Faron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Faron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.